JP2013540732A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540732A5
JP2013540732A5 JP2013528350A JP2013528350A JP2013540732A5 JP 2013540732 A5 JP2013540732 A5 JP 2013540732A5 JP 2013528350 A JP2013528350 A JP 2013528350A JP 2013528350 A JP2013528350 A JP 2013528350A JP 2013540732 A5 JP2013540732 A5 JP 2013540732A5
Authority
JP
Japan
Prior art keywords
linaclotide
pharmaceutical composition
patient
weeks
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013528350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051080 external-priority patent/WO2012034068A1/en
Publication of JP2013540732A publication Critical patent/JP2013540732A/ja
Publication of JP2013540732A5 publication Critical patent/JP2013540732A5/ja
Pending legal-status Critical Current

Links

JP2013528350A 2010-09-11 2011-09-09 便秘型過敏性腸症候群の処置 Pending JP2013540732A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US38193610P 2010-09-11 2010-09-11
US61/381,936 2010-09-11
US38246910P 2010-09-13 2010-09-13
US61/382,469 2010-09-13
US39426710P 2010-10-18 2010-10-18
US61/394,267 2010-10-18
US40850910P 2010-10-29 2010-10-29
US61/408,509 2010-10-29
US40899410P 2010-11-01 2010-11-01
US61/408,994 2010-11-01
PCT/US2011/051080 WO2012034068A1 (en) 2010-09-11 2011-09-09 Treatment of constipation-predominant irritable bowel syndrome

Publications (2)

Publication Number Publication Date
JP2013540732A JP2013540732A (ja) 2013-11-07
JP2013540732A5 true JP2013540732A5 (https=) 2014-10-30

Family

ID=44654514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528350A Pending JP2013540732A (ja) 2010-09-11 2011-09-09 便秘型過敏性腸症候群の処置

Country Status (7)

Country Link
US (9) US20140162963A1 (https=)
EP (1) EP2613794A1 (https=)
JP (1) JP2013540732A (https=)
CN (1) CN103702678A (https=)
CA (1) CA2811001A1 (https=)
MX (1) MX2013002747A (https=)
WO (1) WO2012034068A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
CN105412904A (zh) * 2014-06-17 2016-03-23 深圳翰宇药业股份有限公司 利那洛肽肠溶缓释微丸胶囊制剂及其制备方法和用途
WO2016024291A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
US20220241367A1 (en) * 2019-06-10 2022-08-04 Ironwood Pharmaceutical, Inc. Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN117530912A (zh) * 2008-08-15 2024-02-09 硬木药品公司 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
CA2770334A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
WO2011020054A1 (en) * 2009-08-13 2011-02-17 Ironwood Pharmaceuticals Inc. Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists
US8933030B2 (en) * 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders

Similar Documents

Publication Publication Date Title
Soykan et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease
CA2880742C (en) Combination therapy for treatment of multiple sclerosis
JP2013540732A5 (https=)
FI3710000T3 (fi) Tradipitantti käytettäväksi gastropareesin hoidossa
CN103458911A (zh) 肽组合物和用于治疗患者的方法
CN111032158A (zh) 用于治疗抑郁的nk-1拮抗剂组合物和方法
JP2020522560A5 (https=)
Ali et al. Role of prucalopride in treating functional constipation and gastroparesis: a systemic review
RS60240B1 (sr) Postupci i kompozicije za lečenje depresije korišćenjem ciklobenzaprina
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
JP2015501849A5 (https=)
JP2013540732A (ja) 便秘型過敏性腸症候群の処置
D'Haens et al. P574 The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trial
KR102854371B1 (ko) 에트라비린의 대사성 질환 및 섬유화 질환 치료 용도
TW202245742A (zh) 預防、治療或改善潰瘍性結腸炎的方法
JP2021121603A (ja) 多発性硬化症を処置するための併用療法
KR102916453B1 (ko) 오바토클락스 대사성 질환 및 섬유화 질환 치료 용도
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
JP2022500351A5 (https=)
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
Van Outryve et al. T1400 Long-Term Follow-Up Study of Oral Prucalopride (Resolor®) Administered to Patients with Chronic Constipation
WO2025238423A2 (en) Methods of treating metabolic disorders and combination products for use in the same
Sachdeva et al. No pain, no strain: Targin® mitigates pain and constipation following spinal cord injury
Schöndorf et al. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone—results from a post-marketing surveillance trial under daily routine conditions
Dreesen et al. P572 Reactive dose escalation of infliximab in patients with Crohn’s disease in TAILORIX leads to improved outcomes